scholarly journals Treatment of endometriosis: a review with comparison of 8 guidelines

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dimitrios Rafail Kalaitzopoulos ◽  
Nicolas Samartzis ◽  
Georgios N. Kolovos ◽  
Evangelia Mareti ◽  
Eleftherios Pierre Samartzis ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Reproductive Medicine ◽  
Oral Contraceptive Pill ◽  
Reproductive Age ◽  
Human Reproduction ◽  
Women Of Reproductive Age ◽  
Combined Oral Contraceptive ◽  
Associated Symptoms ◽  
Third Line ◽  
American Society

Abstract Background Endometriosis, the presence of endometrial-like tissue outside the uterus, is a common clinical entity between women of reproductive age, with a prevalence of about 10%. Due to the variety of endometriosis-associated symptoms, a great variety of treatments have been implemented. The aim of this review is to give an overview on therapeutical approaches of eight national and international widely used guidelines. Methods Six national (College National des Gynecologues et Obstetriciens Francais, National German Guideline (S2k), Society of Obstetricians and Gynaecologists of Canada, American College of Obstetricians (ACOG) and Gynecologists, American Society for Reproductive Medicine (ASRM) and National Institute for Health and Care (NICE) and two international (World Endometriosis Society, European Society of Human Reproduction and Embryology) guidelines are included in this review. Conclusion All the above-mentioned guidelines agree that the combined oral contraceptive pill, progestogens are therapies recommended for endometriosis associated pain. Concerning infertility, there is no clear consensus about surgical treatment. Discrepancies are also found on recommendation of the second- and third-line treatments.

Effect of combined oral contraceptive containing 17β—estradiol on female sexual function, depression and quality of life

2020 ◽  
Vol 18 (6) ◽  
pp. 43-48
Author(s):  
R. I. GABIDULLINA ◽  
◽  
E. I. GALIMYANOVA ◽  
V. I. EREMKINA ◽  
A. M. SHARAPOVA ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Oral Contraceptive ◽  
Female Sexuality ◽  
Reproductive Age ◽  
Women Of Reproductive Age ◽  
Combined Oral Contraceptive ◽  
Function Index ◽  
17Β Estradiol ◽  
Severity Of Depression

The purpose — to evaluate the effect of combined oral contraceptive containing 17β-estradiol on sexuality, severity of depression and quality of life in women of reproductive age. Material and methods. The study involved 53 women in need of contraception aged 18 to 50 years. For the contraceptive purpose women used COC containing 1,5 mg of 17 β -estradiol (E2) and 2,5 mg of nomegestrol acetate (NOMAC) (E2/NOMAC). The questionnaires used in the study are: Female Sexuality Function Index (FSFI-6), Beck Depression Inventory, SF-36 — for evaluating Health-Related Quality of Life. The survey was conducted before and after six months of E2/NOMAC intake; the correlations between the studied parameters and the level of sex hormones in patient’s blood sample were determined. Results. The intake of E2/NOMAC for 6 months did not have negative effect on Female Sexuality Function Index. At the same time, a statistically significant improvement up to 5 points was revealed in such parameters as sexual satisfaction (p = 0,03) and lubrication (p < 0,001). There was a significant decrease in the frequency and severity of depression measured by the Beck Depression Inventory. The Short Form-36 Health Survey revealed a tendency to improve the physical and mental health components of the quality of life (p> 0,05). The change in total testosterone level had a moderate negative relationship with the change in Female Sexuality Function Index (r = — 0,32; p = 0,02). Conclusion. The intake of combined oral contraceptive containing 17β-estradiol for 6 months was associated with no adverse impact on female sexuality and quality of life in women of reproductive age, and reduced the levels of frequency and severity of depression.

scholarly journals The association between combined oral contraceptive use and overweight/obesity: a secondary data analysis of the 2016 Ethiopia Demographic and Health Survey

BMJ Open ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. e039229
Author(s):  
Melese Linger Endalifer ◽  
Gedefaw Diress ◽  
Amanuel Addisu ◽  
Bedilu Linger
Keyword(s):  
Oral Contraceptive ◽  
Health Survey ◽  
The Body ◽  
Demographic And Health Survey ◽  
Reproductive Age ◽  
Adult Women ◽  
Negative Consequences ◽  
Women Of Reproductive Age ◽  
Eligibility Criteria ◽  
Combined Oral Contraceptive

ObjectivesIn this study, we aimed to assess the association between combined oral contraceptive (OC) use and overweight/obesity among Ethiopian adult women of reproductive age.Design, setting and participantsThe data were extracted from the 2016 Ethiopia Demographic and Health Survey; these data were collected from nine regions and two city administrations. We analysed the data from a total of 11 018 women aged 18–49 years who met eligibility criteria.Main outcome measuresWe employed WHO criteria to classify the body mass index of women. Specifically we tested the association between combined OC utilisation with overweight/obesity after controlling for confounding variables.ResultThe prevalence of combined OC utilisation was 1.7% and the prevalence of overweight/obesity was 8.6% among adult women of reproductive age. Use of combined OC increases the odds of overweight/obesity by two times among adult women of reproductive age after controlling for potential confounders (adjusted OR=1.902 (1.064–3.399)).ConclusionIn conclusion there is significant association between combined OC use and overweight/obesity. The findings have important implications for policymakers to design evidence based policy approachs to obesity prevention for women and at large for government to recognise the negative consequences of combined OC on women health.

scholarly journals ADMINISTRATION OF A COMBINED ORAL CONTRACEPTIVE CONTAINING ESTRADIOL VALERATE/DIENOGEST (E2V/DNG) BY WOMEN WITH MENORRHAGIA

2017 ◽  
pp. 31-37
Author(s):  
E. R. Dovlethanova ◽  
E. A. Mezhevitinova ◽  
A. N. Mgeryan ◽  
P. R. Abakarova
Keyword(s):  
Oral Contraceptive ◽  
Pathological Condition ◽  
Reproductive Age ◽  
Estradiol Valerate ◽  
Women Of Reproductive Age ◽  
Combined Oral Contraceptives ◽  
Combined Oral Contraceptive ◽  
Quality Life ◽  
Choice Of Therapy ◽  
Excessive Proliferation

Menorrhagia is the pathological condition which is negatively affecting physical, emotional and social quality life of the woman. Medicines of the choice of therapy of uterine bleedings are the combined oral contraceptives (COC). The estradiol valerate/ dienogest (E2V/DNG), represents the combined oral contraceptive (COC) recommended for women as contraceptive. Gives to feature of influence of medicine on endometrium the chance of its application in case of uterine bleedings. The hormones which are a part suppress excessive proliferation of endometrium that leads to reduction of amount of menstrual allocations. Results of a research which confirm successful application of E2V/DNG in case of the menorrhagia at the women of reproductive age in clinical situations who aren’t requiring operational treatment are provided.

Starting oral contraceptives – which, when and how?

1992 ◽  
Vol 30 (11) ◽  
pp. 41-44
Keyword(s):  
Oral Contraceptive ◽  
Sexual Activity ◽  
Medical History ◽  
Oral Contraceptives ◽  
New Products ◽  
Oral Contraceptive Pill ◽  
Oral Contraception ◽  
Planned Parenthood ◽  
Combined Oral Contraceptive ◽  
Free Interval

About one quarter of women in Britain aged 18–44 use oral contraceptives,1 and almost half of those aged 20–29.2 Many will use more than one type during their years of sexual activity. Changes will occur as new products are introduced and new risks identified or in response to unwanted effects. Decisions may also be prompted by the need to restart oral contraception after a break as part of planned parenthood. Oral contraception is chosen chiefly because it is reliable and does not interrupt spontaneous sexual activity. Whether a combined oral contraceptive pill (COC) or a progestagen-only pill (POP) would be the more appropriate depends mainly on the woman’s medical history, smoking habits and age. Most women will want good cycle control, and a few will prefer to take an inactive pill for a few days in each cycle rather than have a pill-free interval. This article discusses the choice when starting, restarting or switching oral contraception.

Sign in / Sign up

Export Citation Format

Share Document